However in another study, Gynecologic Oncology Group (GOG)-0181-B, investigated trastuzumab in advanced, recurrent, or persistent endometrial cancer, and its preliminary results showed minimal activity, even in cancers with high overexpression of HER2/neu [4]. The gene discussed is ERBB2; the disease is cancer.